MRK Merck KGaA
Legal ·
Cronin v. Merck in New Jersey names Merck and unnamed officers. The 10-Q gives no individual defendants; Merck's filings show its CEO, CFO and 13 director nominees.
The radiopharmaceutical developer sold 17.65 million shares on the Nasdaq, the first U.S. biotech IPO of 2026, after raising its offering size.
Merck expects to eliminate certain positions in sales, administrative and research and development organizations and expects annual savings of approximately $1.7 billion, substantially realized by the end of 2027.
Merck & Co., Inc. is a global health care company that delivers innovative health solutions through prescription medicines, including biologic therapies, vaccines and animal health products. It runs two reportable segments, Pharmaceutical and Animal Health. The Pharmaceutical segment sells human health medicines and vaccines, mainly to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. Its lead product is Keytruda (pembrolizumab), an anti-PD-1 therapy approved for many cancer types, and Keytruda Qlex, a subcutaneous fixed combination of pembrolizumab and berahyaluronidase alfa. Welireg (belzutifan) treats certain von Hippel-Lindau disease-associated tumors and advanced renal cell carcinoma. Vaccines include Gardasil 9, which helps prevent certain cancers and diseases caused by human papillomavirus, along with ProQuad, M-M-R II and Varivax. Merck also records alliance revenue from Lynparza and Lenvima, and from Reblozyl. The Animal Health segment develops and markets veterinary pharmaceuticals and vaccines for livestock and companion animals, along with identification, traceability and monitoring products.
| Product or program | What it is | Stage |
|---|---|---|
| Keytruda (pembrolizumab) | Anti-PD-1 therapy for many solid tumors and lymphomas | approved |
| Keytruda Qlex | Subcutaneous fixed combination of pembrolizumab and berahyaluronidase alfa | approved in the U.S. |
| Welireg (belzutifan) | Treats certain VHL disease-associated tumors and advanced renal cell carcinoma | approved |
| Gardasil 9 | HPV vaccine to help prevent certain cancers and diseases |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $65.01 billion | $64.17 billion |
| Research and development | $15.79 billion | $17.94 billion |
| Net income (loss) | $18.25 billion | $17.12 billion |
| Cash from operations | $16.47 billion | $21.47 billion |
| Cash and equivalents | $14.56 billion | $13.24 billion |
| Short-term investments | $0 | $447.0 million |
Our latest story on this, dated Aug 7, 2026: "Merck faces securities class action over Gardasil demand in China, with derivative suits stayed". The story links the filing or release it is based on. Read the story.
Merck KGaA trades under the ticker MRK on XETR.
Merck KGaA is listed on XETR. Our directory also records these other listings: BSESOF:MRK; DUS:MRK; EUROTLX:4MRK; FWB:MRK; GETTEX:MRK; HAM:MRK; HAN:MRK; LS:659990; LSIN:0O14; LSX:659990; MUN:MRK; OTC:MKGAF; OTC:MKKGY; SIX:MER; SWB:MRK; TRADEGATE:MRK; VIE:MRCK.
Our directory records Merck KGaA under Germany.
Our directory classifies Merck KGaA as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Merck KGaA is DE0006599905.
aibio.space lists Merck KGaA among 2,820 public biotech companies and publishes its news here as stories appear.
Merck & Co., Inc. is a global health care company that delivers innovative health solutions through prescription medicines, including biologic therapies, vaccines and animal health products. It runs two reportable segments, Pharmaceutical and Animal Health.
Keytruda (pembrolizumab): Anti-PD-1 therapy for many solid tumors and lymphomas Stage: approved.
Keytruda Qlex: Subcutaneous fixed combination of pembrolizumab and berahyaluronidase alfa Stage: approved in the U.S..
$65.01 billion for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Merck KGaA reported net income of $18.25 billion for the fiscal year ended Dec 31, 2025, and generated $16.47 billion of cash from operations, per its annual report to the SEC.
$15.79 billion in the fiscal year ended Dec 31, 2025, per its annual report.
$7.14 billion in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Merck KGaA, dated Aug 7, 2026: "Merck faces securities class action over Gardasil demand in China, with derivative suits stayed". Cronin v. Merck in New Jersey names Merck and unnamed officers. The 10-Q gives no individual defendants; Merck's filings show its CEO, CFO and 13 director nominees. Source.
Reported a financing. SEC Form 424B5. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
A tender offer for its shares was filed. SEC Form SC TO-T. Source
A tender offer for its shares was filed. SEC Form SC TO-T. Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 424B5. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio